This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

34/100

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded beyond glycemic control to include cardiovascular and renal risk reduction, with recent approval for reducing major adverse cardiovascular events in individuals with obesity or overweight and established cardiovascular disease. Increasing attention has focused on their potential applications in neurodegenerative disorders and substance use disorders (SUDs), supported by mechanistic links to neuroinflammation, mitochondrial function, and central reward pathways. However, clinical evidence remains heterogeneous and disease-specific, with discordance between biological mechanisms, biomarker changes. In Alzheimer disease, phase 3 trials of oral semaglutide (EVOKE and EVOKE+) did not demonstrate slowing of clinical progression despite biomarker effects. In Parkinson disease, early-phase signals suggesting benefit have not been replicated in larger trials, arguing against a consistent class effect. In alcohol use disorder, randomized and observational studies suggest reductions in craving and alcohol-related outcomes, although residual confounding remains substantial. Current evidence does not support off-label use of GLP-1RAs for neurodegenerative disease or SUDs. For clinicians, their role remains within approved cardiometabolic indications, with emerging relevance in comorbidity recognition, safety monitoring, and consideration of clinical trial referral.These findings are particularly relevant for general internists managing patients with overlapping cardiometabolic disease, cognitive impairment, and substance use disorders.

Key findings

For clinicians, their role remains within approved cardiometabolic indications, with emerging relevance in comorbidity recognition, safety monitoring, and consideration of clinical trial referral.These findings are particularly relevant for general internists managing patients with overlapping cardiometabolic disease, cognitive impairment, and substance use disorders.

Why it matters

This review states that phase 3 trials of oral semaglutide in Alzheimer's disease did not slow clinical progression despite effects on biomarkers. It concludes that current evidence does not support using GLP-1 receptor agonists for neurodegenerative disease outside approved cardiometabolic indications.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Study designclinical trial
Evidence strengthHigh

How this study scored 34/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 33 of the 96 points we could judge it on, which is 34 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Community Hospital Internal Medicine Perspectives)
Journal's citation record	0 / 4	Journal of Community Hospital Internal Medicine Perspectives: journal h-index 41 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Zaki Azam holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record	2 / 3	New York University: institution h-index 1,612 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	33 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 33 of the 96 points we could judge it on is 34 out of 100.
Total	34 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Raja, M., Patel, K., Krish, P., Chow, C., & Azam, Z. (2026). GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders. Journal of Community Hospital Internal Medicine Perspectives. https://doi.org/10.55729/2000-9666.1651

Vancouver

Raja M, Patel K, Krish P, Chow C, Azam Z. GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders. Journal of Community Hospital Internal Medicine Perspectives. 2026. doi:10.55729/2000-9666.1651.

BibTeX

@article{raja2026-d1c44bbc,
  author  = {Raja, Michelle and Patel, Khush and Krish, Pranav and Chow, Chrissy and Azam, Zaki},
  title   = {{GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders}},
  journal = {Journal of Community Hospital Internal Medicine Perspectives},
  year    = {2026},
  doi     = {10.55729/2000-9666.1651},
  url     = {https://doi.org/10.55729/2000-9666.1651}
}

Related studies in Drug development

Also in Drug development

79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →